Compare Citius Pharmaceuticals Inc (CTXR) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Uranium Energy Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Uranium Energy Corp trades at $10.12 (market cap $5.14B). The key difference: Uranium Energy Corp is far larger — about 351.1× Citius Pharmaceuticals Inc's market cap, and Uranium Energy Corp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | UEC | |
|---|---|---|
Market Cap | $14.64M | $5.14B |
Sector | Health | Energy |
52-Week High | $1.82 | $20.14 |
52-Week Low | $0.53 | $6.98 |
Enterprise Value | $10.86M | $4.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Uranium Energy (UEC) trades at $10.07, down 4.37% today, reflecting ongoing operational challenges. The stock shows a bearish technical trend with key support at $10. Fundamentally, the company reported a net loss of $87.66 million in 2025 on $66.84 million revenue, with negative margins and a high P/S ratio of 242.83. Recent news highlights strategic positioning in U.S. uranium production but notes execution risks and cost pressures.
The outlook remains speculative; UEC's $794 million liquidity and debt-free balance sheet support growth initiatives, but persistent losses and volatile earnings create significant risk. Analyst consensus is 87.5% buy, targeting production ramp-ups, yet investors face uncertainty from licensing delays and uranium price fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
